Amicus Therapeutics, Inc. (NASDAQ:FOLD) CFO William D. Baird III sold 40,000 shares of the company’s stock in a transaction on Thursday, October 12th. The shares were sold at an average price of $14.25, for a total transaction of $570,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) traded up 1.45% during trading on Monday, hitting $14.74. 2,070,898 shares of the stock traded hands. The company’s market cap is $2.43 billion. Amicus Therapeutics, Inc. has a 52 week low of $4.41 and a 52 week high of $16.60. The firm’s 50-day moving average price is $14.39 and its 200-day moving average price is $10.90.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The company had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter in the prior year, the business earned ($0.40) earnings per share. On average, equities research analysts anticipate that Amicus Therapeutics, Inc. will post ($1.32) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/william-d-baird-iii-sells-40000-shares-of-amicus-therapeutics-inc-fold-stock/1635222.html.

A number of brokerages have commented on FOLD. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 6th. Chardan Capital reissued a “buy” rating and issued a $18.50 price objective (up from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Robert W. Baird reissued an “outperform” rating and issued a $18.00 price objective (up from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Finally, J P Morgan Chase & Co reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.81.

Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA lifted its stake in Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock valued at $685,000 after buying an additional 66,209 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Amicus Therapeutics by 5.7% during the first quarter. Goldman Sachs Group Inc. now owns 777,146 shares of the biopharmaceutical company’s stock worth $5,541,000 after purchasing an additional 41,711 shares during the period. State of Wisconsin Investment Board acquired a new stake in shares of Amicus Therapeutics during the second quarter worth about $1,057,000. Geode Capital Management LLC raised its position in shares of Amicus Therapeutics by 4.7% during the first quarter. Geode Capital Management LLC now owns 1,167,356 shares of the biopharmaceutical company’s stock worth $8,323,000 after purchasing an additional 52,003 shares during the period. Finally, Morgan Stanley raised its position in shares of Amicus Therapeutics by 99.4% during the first quarter. Morgan Stanley now owns 6,128,481 shares of the biopharmaceutical company’s stock worth $43,696,000 after purchasing an additional 3,055,039 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.